nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,days_since_update
NCT04280705,"ClinicalTrials.gov processed this data on November 06, 2020",2020-02-20,2020-09-16,NA,2020-11-01,2020-02-20,2020-02-21,Actual,2020-09-22,2020-09-25,Actual,NA,NA,NA,2020-11-01,2020-11-03,Actual,"February 21, 2020",Actual,2020-02-21,April 2020,2020-04-30,"May 21, 2020",Actual,2020-05-21,"May 21, 2020",Actual,2020-05-21,NA,Interventional,NA,,Adaptive COVID-19 Treatment Trial (ACTT),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults",Completed,NA,Phase 3,1062,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-07T11:27:08Z,2020-11-07T11:27:08Z,14
NCT04343092,"ClinicalTrials.gov processed this data on November 06, 2020",2020-04-05,2020-06-11,NA,2020-11-02,2020-04-08,2020-04-13,Actual,2020-11-02,2020-11-04,Actual,NA,NA,NA,2020-11-02,2020-11-04,Actual,"April 18, 2020",Actual,2020-04-18,November 2020,2020-11-30,"June 1, 2020",Actual,2020-06-01,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (An Externally Controlled Pilot Trial),Completed,NA,Phase 1,16,Actual,University of Baghdad,"small sample size; single center design, and short time for the study",1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-08T11:36:16Z,2020-11-08T11:36:16Z,13
NCT04343261,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,2020-09-01,NA,2020-09-22,2020-04-08,2020-04-13,Actual,2020-09-15,2020-09-17,Actual,NA,NA,NA,2020-09-22,2020-09-24,Actual,"April 10, 2020",Actual,2020-04-10,September 2020,2020-09-30,"August 13, 2020",Actual,2020-08-13,"July 23, 2020",Actual,2020-07-23,NA,Interventional,NA,,Convalescent Plasma in the Treatment of COVID 19,Convalescent Plasma in the Treatment of COVID 19,Completed,NA,Phase 2,48,Actual,Saint Francis Care,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:32Z,2020-11-01T12:06:32Z,54
NCT04410159,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-27,2020-07-08,NA,2020-07-17,2020-05-28,2020-06-01,Actual,2020-07-17,2020-07-21,Actual,NA,NA,NA,2020-07-17,2020-07-21,Actual,"June 22, 2020",Actual,2020-06-22,July 2020,2020-07-31,"July 6, 2020",Actual,2020-07-06,"June 29, 2020",Actual,2020-06-29,NA,Interventional,GARGLES,,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,"A Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 Patients",Completed,NA,Phase 2,20,Actual,Universiti Sains Islam Malaysia,Inadequate budget for laboratory test lead to small numbers of subjects analyzed,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,September to December 2020,email to drnurul@usim.edu.my,NA,Yes,The participant data from the final research dataset used in the published manuscript will be shared upon reasonable request. The protocol and data analysis will be shared in clinicaltrial,2020-11-01T11:57:45Z,2020-11-01T11:57:45Z,121
NCT04422561,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-06,2020-08-23,NA,2020-08-23,2020-06-06,2020-06-09,Actual,2020-08-23,2020-08-27,Actual,NA,NA,NA,2020-08-23,2020-08-27,Actual,"May 31, 2020",Actual,2020-05-31,August 2020,2020-08-31,"July 27, 2020",Actual,2020-07-27,"July 14, 2020",Actual,2020-07-14,NA,Interventional,NA,,Prophylactic Ivermectin in COVID-19 Contacts,Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19,Completed,NA,Phase 2/Phase 3,340,Actual,Zagazig University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:56:10Z,2020-11-01T11:56:10Z,84
NCT04491240,"ClinicalTrials.gov processed this data on November 06, 2020",2020-07-27,2020-10-21,NA,2020-10-28,2020-07-27,2020-07-29,Actual,2020-10-28,2020-11-04,Actual,NA,NA,NA,2020-10-28,2020-11-04,Actual,"July 20, 2020",Actual,2020-07-20,October 2020,2020-10-31,"October 20, 2020",Actual,2020-10-20,"October 1, 2020",Actual,2020-10-01,NA,Interventional,COVID-19EXO,,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,The Protocol of Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Two-Sided Pneumonia,Completed,NA,Phase 1/Phase 2,30,Actual,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-08T11:33:20Z,2020-11-08T11:33:20Z,18
NCT04491994,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-28,2020-07-31,NA,2020-08-18,2020-07-28,2020-07-30,Actual,2020-08-18,2020-08-21,Actual,NA,NA,NA,2020-08-18,2020-08-21,Actual,"April 10, 2020",Actual,2020-04-10,August 2020,2020-08-31,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,COVID-19,sample size calculation was done and 540 patients enrolled,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial,Completed,NA,Phase 3,540,Actual,UNICEF,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,any time when asked,by email,NA,Yes,data can be shared on demand in SPSS sheet,2020-11-01T11:47:46Z,2020-11-01T11:47:46Z,89
NCT04523831,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-19,2020-09-30,NA,2020-10-07,2020-08-20,2020-08-24,Actual,2020-10-07,2020-10-09,Actual,NA,NA,NA,2020-10-07,2020-10-09,Actual,"June 1, 2020",Actual,2020-06-01,October 2020,2020-10-31,"September 10, 2020",Actual,2020-09-10,"August 22, 2020",Actual,2020-08-22,NA,Interventional,NA,We followed intention to treat analysis; SPSS (Statistical Package for Social Sciences) version 20 was used to analyze data. To compare mean of the two group chi square test was done.,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,A Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard Care,Completed,NA,Phase 3,400,Actual,Dhaka Medical College,"We followed up the patients by telephonic (video) interview, which has some inherent drawback for the study. we could not assess viral clearance directly. Only single dose regimen was used. Efficacy might higher if the different regimen would use.",2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,September 2020 to December 2020,Person who are investigating covid-19 in various aspects,NA,Yes,"Patients age, sex, Date of covid positive report, Symtoms,Date of covid negative report, post covid symptoms, time to recover.",2020-11-01T11:44:05Z,2020-11-01T11:44:05Z,39
NCT04542694,"ClinicalTrials.gov processed this data on November 06, 2020",2020-09-04,2020-10-11,NA,2020-11-03,2020-09-04,2020-09-09,Actual,2020-11-03,2020-11-05,Actual,NA,NA,NA,2020-11-03,2020-11-05,Actual,"May 21, 2020",Actual,2020-05-21,November 2020,2020-11-30,"August 20, 2020",Actual,2020-08-20,"August 10, 2020",Actual,2020-08-10,NA,Interventional,NA,,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,"Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of Areplivir Film-coated Tablets (PROMOMED RUS LLC, Russia) in Patients Hospitalized With COVID-19",Completed,NA,Phase 3,200,Actual,"Promomed, LLC",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-09T10:51:55Z,2020-11-09T10:51:55Z,12
